Evaluating Conformal Reliability of Pathway-Level Transcriptomic Signatures Under Cross-Cohort Shift in Sepsis Mortality Prediction

Introduction to the show: ident: Genomics Radio. Generated commentary on the latest computational biology and genomics papers.

Ines: We're looking at the paper: "Evaluating Conformal Reliability of Pathway-Level Transcriptomic Signatures Under Cross-Cohort Shift in Sepsis Mortality Prediction".

Marcus: Here's the gist of the paper. The gist The study presents a framework for evaluating transcriptomic sepsis mortality prediction under realistic cross-cohort deployment by systematically comparing genelevel, pathway-level, and hybrid molecular representations.

Ines: How it works The researchers developed a framework to evaluate transcriptomic sepsis mortality prediction under realistic cohort shifts using four publicly available whole-blood transcriptomic cohorts consisting of 936 patients and 248 mortality events The data was harmonized into a shared feature space containing 7,660 genes and three complementary representations of gene-level expression, Hallmark pathway activity scores and a hybrid gene-and-pathway representation Each individual representation was afterwards assessed under leave-one-cohort-out (LOCO) validation using logistic regression, random forest, XGBoost and LightGBM Molecular Representations Compared The study systematically compared genelevel, pathwaylevel and hybrid molecular representations Gene-level and hybrid representations were found to generally achieve the strongest discriminative performance However, pathway-level representations exhibited greater robustness across model families Pathway aggregation at the pathway level is able to reduce dimensionality but may sacrifice on bare predictive resolution Evaluation Metrics Beyond Discrimination Beyond AUROC and AUPRC, model behavior was evaluated via conformal prediction, calibration analysis, selective prediction and the proposed Pathway Stability Index The framework assessed "conformal reliability," "calibration," "abstention behavior" and "feature stability" under LOCO shift instead of solely AUROC and AUPRC Pathway Stability Index (PSI) A Pathway Stability Index (PSI) based upon resampling and directional reproducibility analyses was also introduced for quantifying stable transferable signals PSI successfully separated biological signals that generalized across independent cohorts from associations that were unique to individual datasets High-PSI pathways, as defined by (3), had considerably greater external reproducibility compared to low-PSI pathways and also simultaneously exhibited higher selection frequency and directional consistency Key Findings on Reliability The analyses indicate that deployment-relevant model behavior under cross-cohort shift is influenced by representation choice Compared with pathwaylevel models, genelevel and hybrid models may achieve stronger raw discrimination under some settings; however, pathwaylevel representations can provide a lower-dimensional and reliability-favoring trade-off with improved stability, uncertainty behavior and biological coherence The central recommendation is therefore not that one representation is universally best Biological Interpretation of Stability PSI-ranked genes were also subjected to Gene Ontology and KEGG enrichment analysis to determine whether highly stable transcriptomic features corresponded to established sepsis pathophysiology mechanisms Immune and host-defense processes were the highest ranking enrichment terms These findings indicate PSI to be most useful when paired with functional enrichment and domain knowledge The study concludes that maximizing AUROC or AUPRC alone is insufficient when developing models intended for deployment across independent clinical settings Molecular representation influences not only predictive performance but also the reliability, interpretability, and transferability of transcriptomic prognostic models The findings denote that maximizing AUROC or AUPRC alone is insufficient when developing models intended for deployment across independent clinical settings> Limitations There remains considerable heterogeneity among cohort sizes and transcriptomic platforms Conformal guarantees decrease as the extent of distribution shift increases Additional validation will be required to ensure that PSI performs similarly across larger and more diverse datasets

Paper summary: Marcus: We've just touched on the framework used in "Evaluating Conformal Reliability of Pathway-Level Transcriptomic Signatures Under Cross-Cohort Shift in Sepsis Mortality Prediction," where they set up a system to test prediction models under real deployment scenarios. Basically, they are taking transcriptomic sepsis mortality prediction and looking at how it handles shifts between different patient groups.

Ines: The thesis here is that within-cohort evaluation strategies used by most transcriptomic models don't reflect the reality of deploying them across independent hospitals, which causes a cohort shift that degrades both predictive performance and the reliability of uncertainty estimates <ref:2607.17405#pg2>.

Yuki: So, they are addressing that gap between lab results and clinical reality where patient metrics and clinical practices change significantly, leading to what they call a significant cohort shift in sepsis transcriptomics <ref:2607.17405#pg2>.

Marcus: To do this, they present a framework that systematically compares three types of molecular representations: gene-level, pathway-level, and hybrid ones. They use four public cohorts with nine hundred thirty-six patients and two hundred forty-eight mortality events to test these representations using leave-one-cohort-out validation with logistic regression, random forests, XGBoost, and LightGBM <ref:2607.17405#pg1>.

Ines: They then evaluate the models not just on metrics like AUROC or AUPRC, but also on conformal prediction and calibration analysis to gauge how trustworthy the model is when it sees new data <ref:2607.17405#pg2>.

Yuki: And they introduce the Pathway Stability Index, or PSI, which is designed to quantify stable transferable signals by looking at resampling and directional reproducibility <ref:2607.17405#pg3>.

Marcus: The main takeaway from this summary is that the paper systematically compares these representations to find out which one offers better balance between predictive power and stability when facing external validation challenges <ref:2607.17405#pg2>.

Conclusion: Ines: To wrap up, the authors of "Evaluating Conformal Reliability of Pathway-Level Transcriptomic Signatures Under Cross-Cohort Shift in Sepsis Mortality Prediction" argue that we need to evaluate transcriptomic prognostic models jointly across discrimination, calibration, uncertainty reliability, and biological reproducibility <ref:2607.17405#pg3>.

Marcus: They show that while gene-level and hybrid models might have the strongest raw discrimination under certain conditions, pathway-level representations can offer a lower-dimensional trade-off with improved stability and better uncertainty behavior when moving between cohorts <ref:2607.17405#pg2>.

Yuki: And they link this stability back to biology by finding that highly stable features tend to be enriched for immune and host-defense processes, which gives context to why those pathways are reliable signals <ref:2607.17405#pg3>.

Ines: So, the main implication is that maximizing AUROC or AUPRC alone isn't sufficient when we develop these models because it misses the crucial aspects of transferability and reliability in a real clinical setting <ref:2607.17405#pg3>.